Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)

NCT04629144 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Vasculitis
Cryoglobulinemia

Interventions

DRUG: Belimumab
DRUG: Placebo

Sponsor

Assistance Publique - Hôpitaux de Paris